Telix ADSs Commence Trading on Nasdaq
Telix announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol...
Read moreLatest News
Category: News
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
Telix today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce...
Read more
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
Telix today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals for Medicare Fee for...
Read more
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
News,
Telix today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix’s commercial PSMA-PET product, Illuccix®...
Read more
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®), an agent for the imaging of glioma....
Read more
Telix to Spin Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
Telix today announces the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m(99mTc) and...
Read more
Telix Files Form 20-F Registration Statement for Nasdaq ADS
Telix announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of...
Read more
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
Telix today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3...
Read more
Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Association...
Read more
Australian TGA Approves Additional Indication for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
News,
Telix today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of 68Ga-PSMA-11[1] injection) to select patients for PSMA[2]-targeted radionuclide...
Read more